TCGX Acquisition Corp. II prices $100M IPO for healthcare focus
- Priced 10,000,000 shares at $10.00 each for $100,000,000 gross proceeds
- Listing on Nasdaq under ticker TCXB starting October 16, 2026
- No warrants issued to investors, differing from typical SPAC structures
- Focuses on healthcare, life sciences, and medical technology acquisitions
*this image is generated using AI for illustrative purposes only.
TCGX Acquisition Corp. II priced its initial public offering of 10,000,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $100,000,000. The special purpose acquisition company (SPAC) will list on The Nasdaq Capital Market under the ticker symbol "TCXB" beginning October 16, 2026.
Unlike many other SPAC offerings, investors in this deal will not receive warrants that become exercisable after the completion of the company's initial business combination. This structural difference distinguishes the offering from standard market practices where warrant coverage is common.
Offering structure and timeline
The offering is expected to close on or about October 19, 2026, subject to customary closing conditions. Guggenheim Securities is acting as the sole book-running manager for the transaction. Notably, the offering does not include an over-allotment option, limiting the maximum capital raise to the announced amount.
| Detail | Information |
|---|---|
| Shares Offered | 10,000,000 Class A ordinary shares |
| Price Per Share | $10.00 |
| Gross Proceeds | $100,000,000 |
| Ticker Symbol | TCXB |
| Listing Date | October 16, 2026 |
| Expected Close | October 19, 2026 |
Strategic focus and sponsorship
The company is sponsored by TCGX Sponsor II, LLC, an affiliate of TCG Crossover Management, LLC. While TCGX Acquisition Corp. II may pursue acquisition opportunities in any business, industry sector, or geographical location, it intends to focus its search on the healthcare and healthcare-related industries. Specific attention will be directed toward the life sciences and medical technology sectors.
The registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on October 15, 2026. The offering is being made only by means of a prospectus, with copies available from Guggenheim Securities, LLC.
How will the absence of warrant coverage impact TCGX Acquisition Corp. II's ability to attract institutional investors compared to competitors offering traditional SPAC structures?
Which specific life sciences or medtech companies are currently in advanced negotiations or rumored to be potential acquisition targets for the healthcare-focused SPAC?
What strategic advantages does the lack of an over-allotment option provide to the sponsor regarding dilution control and post-merger equity stability?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
